Small Molecule Inhibition of Deubiquitinating Enzyme JOSD1 as a Novel Targeted Therapy for Leukemias with Mutant JAK2

Researchers presented a strategy to target mutated JAK2 for degradation, using the cell’s intracellular degradation machinery, while sparing non-mutated JAK2, and found that targeting JOSD1 led to the death of JAK2-V617F-positive primary acute myeloid leukemia cells.